Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company developing novel serotonergic agonists (NSAs), announced that Interim Chief Executive Officer Eric So will participate in a fireside chat at the Jefferies Global Healthcare Conference in New York. The discussion is scheduled for June 4, 2026, at 2:35 p.m. EDT and will be webcast live, with a replay available through the Events & Presentations section of the company’s investor relations website. The full press release is available at https://ibn.fm/1QdP7.
Helus Pharma, the commercial operating name of Cybin Inc., is committed to developing NSAs—synthetic molecules designed to activate serotonin pathways believed to promote neuroplasticity. These investigational therapies aim to address the large unmet need for individuals suffering from depression, anxiety, and other mental health conditions. The company’s lead candidate, HLP003, is in Phase 3 clinical development for the adjunctive treatment of major depressive disorder and has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. Additionally, HLP004 is in Phase 2 for generalized anxiety disorder. The company also maintains an extensive research portfolio of investigational NSAs.
The Jefferies Global Healthcare Conference is a key event for the biopharmaceutical industry, attracting investors, analysts, and executives. Helus Pharma’s participation provides a platform to discuss its clinical programs and the potential of NSAs to offer durable improvements in mental health. The company’s focus on neuroplasticity distinguishes its approach from traditional antidepressants, which often have delayed onset and limited efficacy. With class-leading data, Helus Pharma aims to improve the treatment landscape through therapies that may provide lasting benefits.
Helus Pharma operates in Canada, the United States, the United Kingdom and Ireland. For company updates, visit www.helus.com or follow the team on X, LinkedIn, YouTube and Instagram. The latest news and updates relating to HELP are available in the company’s newsroom at https://ibn.fm/HELP.
The announcement underscores the growing interest in psychedelic-inspired therapies for mental health. Helus Pharma’s NSAs are designed to activate serotonin pathways without the hallucinogenic effects associated with classic psychedelics, potentially offering a more acceptable treatment option. The Phase 3 trial for HLP003 represents a critical step toward regulatory approval, and the Breakthrough Therapy Designation expedites development and review. If successful, HLP003 could become a first-in-class treatment for major depressive disorder, a condition affecting millions worldwide. Similarly, HLP004 addresses generalized anxiety disorder, a common but often undertreated condition.
The fireside chat at the Jefferies conference will likely cover clinical trial results, regulatory strategy, and market potential. Investors and analysts will be keen to hear about the timeline for data readouts and potential commercialization. Helus Pharma’s participation highlights its commitment to advancing mental health treatments and engaging with the investment community.
